CEACAM5 and gastric cancer: Through a binary logistic regression, the combination of CEA, CA19-9, and CA72-4 was found to exhibit an improved evaluation of therapeutic efficiency for GC patients (AUC 0.655; 95% CI, 0.587–0.723) relative to any individual biomarker (Fig. 4B and Table 3).